Aarmed Bio-Science Profile
Key Indicators
- Authorised Capital ₹ 3.00 Cr
as on 16-11-2024
- Paid Up Capital ₹ 1.00 Cr
as on 16-11-2024
- Company Age 5 Year, 29 Days
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 12.57 Cr
as on 16-11-2024
- Revenue %
(FY 2023)
- Profit -109.40%
(FY 2023)
- Ebitda -73.10%
(FY 2023)
- Net Worth -151.06%
(FY 2023)
- Total Assets 20.04%
(FY 2023)
About Aarmed Bio-Science
The Company is engaged in the Food And Beverages Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 3.00 Cr and a paid-up capital of Rs 1.00 Cr.
The company currently has active open charges totaling ₹12.57 Cr.
Jyoti Agrawal, Bhupendra Shah, Lalit Malara, and Two other members serve as directors at the Company.
- CIN/LLPIN
U15549GJ2019PTC110993
- Company No.
110993
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
25 Nov 2019
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Ahmedabad
Industry
Company Details
- Location
Ahmedabad, Gujarat, India
- Telephone
- Email Address
- Social Media-
Who are the key members and board of directors at Aarmed Bio-Science?
Board Members(5)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Jyoti Agrawal  | Director | 25-Nov-2019 | Current |
| Bhupendra Shah | Director | 25-Nov-2019 | Current |
| Lalit Malara | Director | 23-Apr-2022 | Current |
| Aakash Asawa | Director | 25-Nov-2019 | Current |
| Hardik Sukhwal | Director | 25-Nov-2019 | Current |
Financial Performance of Aarmed Bio-Science.
Aarmed Bio-Science Private Limited, for the financial year ended 2023, experienced no change in revenue, with a 0% increase. The company also saw a substantial fall in profitability, with a 109.4% decrease in profit. The company's net worth observed a substantial decline by a decrease of 151.06%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Aarmed Bio-Science?
In 2023, Aarmed Bio-Science had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
- Marthand Luxury And Leisure Private LimitedActive 4 months 19 days
Hardik Sukhwal is a mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 19 Mar 2021 | ₹5.50 Cr | Open |
Others Creation Date: 26 Feb 2021 | ₹7.07 Cr | Open |
How Many Employees Work at Aarmed Bio-Science?
Unlock and access historical data on people associated with Aarmed Bio-Science, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Aarmed Bio-Science, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Aarmed Bio-Science's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
